These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 19362466

  • 1. Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium.
    Geoerger B, Morland B, Ndiaye A, Doz F, Kalifa G, Geoffray A, Pichon F, Frappaz D, Chatelut E, Opolon P, Hain S, Boderet F, Bosq J, Emile JF, Le Deley MC, Capdeville R, Vassal G, Innovative Therapies for Children with Cancer European Consortium.
    Eur J Cancer; 2009 Sep; 45(13):2342-51. PubMed ID: 19362466
    [Abstract] [Full Text] [Related]

  • 2. A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours.
    Baruchel S, Sharp JR, Bartels U, Hukin J, Odame I, Portwine C, Strother D, Fryer C, Halton J, Egorin MJ, Reis RM, Martinho O, Stempak D, Hawkins C, Gammon J, Bouffet E.
    Eur J Cancer; 2009 Sep; 45(13):2352-9. PubMed ID: 19505817
    [Abstract] [Full Text] [Related]

  • 3. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
    Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, Soulieres D, Dirnhofer S, Harlow A, Town A, McKinley A, Supple SG, Seymour J, Di Scala L, van Oosterom A, Herrmann R, Nikolova Z, McArthur AG, Imatinib Target Exploration Consortium Study B2225.
    Clin Cancer Res; 2008 May 01; 14(9):2717-25. PubMed ID: 18451237
    [Abstract] [Full Text] [Related]

  • 4. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
    Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A, Siu LL.
    J Clin Oncol; 2005 Jan 20; 23(3):585-90. PubMed ID: 15659505
    [Abstract] [Full Text] [Related]

  • 5. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
    Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA.
    Cancer; 2006 May 01; 106(9):2005-11. PubMed ID: 16565971
    [Abstract] [Full Text] [Related]

  • 6. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
    Do I, Araujo ES, Kalil RK, Bacchini P, Bertoni F, Unni KK, Park YK.
    Pathol Res Pract; 2007 May 01; 203(3):127-34. PubMed ID: 17298867
    [Abstract] [Full Text] [Related]

  • 7. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.
    Mace J, Sybil Biermann J, Sondak V, McGinn C, Hayes C, Thomas D, Baker L.
    Cancer; 2002 Dec 01; 95(11):2373-9. PubMed ID: 12436445
    [Abstract] [Full Text] [Related]

  • 8. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D, Mondick JT, Jayaraman B, Thompson PA, Blaney SM, Bernstein M, Bond M, Champagne M, Fossler MJ, Barrett JS.
    Cancer Chemother Pharmacol; 2009 Jan 01; 63(2):229-38. PubMed ID: 18398615
    [Abstract] [Full Text] [Related]

  • 9. Expression of c-kit and platelet-derived growth factor receptors in ovarian granulosa cell tumors.
    Rocconi RP, Matthews KS, Kimball KJ, Conner MG, Baker AC, Barnes MN.
    Reprod Sci; 2008 Sep 01; 15(7):673-7. PubMed ID: 18492696
    [Abstract] [Full Text] [Related]

  • 10. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C.
    Leuk Res; 2008 Dec 01; 32(12):1830-6. PubMed ID: 18571721
    [Abstract] [Full Text] [Related]

  • 11. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
    Le Cesne A, Blay JY, Bui BN, Bouché O, Adenis A, Domont J, Cioffi A, Ray-Coquard I, Lassau N, Bonvalot S, Moussy A, Kinet JP, Hermine O.
    Eur J Cancer; 2010 May 01; 46(8):1344-51. PubMed ID: 20211560
    [Abstract] [Full Text] [Related]

  • 12. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
    Schilder RJ, Sill MW, Lee RB, Shaw TJ, Senterman MK, Klein-Szanto AJ, Miner Z, Vanderhyden BC.
    J Clin Oncol; 2008 Jul 10; 26(20):3418-25. PubMed ID: 18612157
    [Abstract] [Full Text] [Related]

  • 13. Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas.
    Orzan F, Terreni MR, Longoni M, Boari N, Mortini P, Doglioni C, Riva P.
    Oncol Rep; 2007 Jul 10; 18(1):249-52. PubMed ID: 17549375
    [Abstract] [Full Text] [Related]

  • 14. [Imatinib and solid tumours].
    Arifi S, El Sayadi H, Dufresne A, Ray-Coquard I, Fayette J, Méeus P, Ranchère D, Decouvelaere AV, Alberti L, Tabone-Eglinger S, Blay JY, Cassier P.
    Bull Cancer; 2008 Jan 10; 95(1):99-106. PubMed ID: 18230575
    [Abstract] [Full Text] [Related]

  • 15. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.
    Tamborini E, Miselli F, Negri T, Lagonigro MS, Staurengo S, Dagrada GP, Stacchiotti S, Pastore E, Gronchi A, Perrone F, Carbone A, Pierotti MA, Casali PG, Pilotti S.
    Clin Cancer Res; 2006 Dec 01; 12(23):6920-8. PubMed ID: 17145809
    [Abstract] [Full Text] [Related]

  • 16. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I, Akisue T, Hara H, Fujimoto T, Imabori M, Doita M, Kuroda R, Fujioka H, Kawamoto T, Yamamoto T, Kurosaka M.
    Anticancer Res; 2007 Dec 01; 27(1A):423-9. PubMed ID: 17352263
    [Abstract] [Full Text] [Related]

  • 17. Response of histiocytoses to imatinib mesylate: fire to ashes.
    Janku F, Amin HM, Yang D, Garrido-Laguna I, Trent JC, Kurzrock R.
    J Clin Oncol; 2010 Nov 01; 28(31):e633-6. PubMed ID: 20733125
    [No Abstract] [Full Text] [Related]

  • 18. Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
    Koon HB, Bubley GJ, Pantanowitz L, Masiello D, Smith B, Crosby K, Proper J, Weeden W, Miller TE, Chatis P, Egorin MJ, Tahan SR, Dezube BJ.
    J Clin Oncol; 2005 Feb 10; 23(5):982-9. PubMed ID: 15572730
    [Abstract] [Full Text] [Related]

  • 19. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA, Steeghs N, Verweij J, Bloem JL, Christensen O, van Doorn L, Ouwerkerk J, de Jonge MJ, Nortier JW, Kraetzschmar J, Rajagopalan P, Gelderblom H.
    J Clin Oncol; 2009 Sep 01; 27(25):4169-76. PubMed ID: 19636022
    [Abstract] [Full Text] [Related]

  • 20. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.
    Modi S, Seidman AD, Dickler M, Moasser M, D'Andrea G, Moynahan ME, Menell J, Panageas KS, Tan LK, Norton L, Hudis CA.
    Breast Cancer Res Treat; 2005 Mar 01; 90(2):157-63. PubMed ID: 15803362
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.